BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 12702132)

  • 1. T-lymphocyte populations in hepatitis C and HIV co-infected patients treated with interferon-alfa-2a and ribavirin.
    Neau D; Galpérine T; Legrand E; Pitard V; Neau-Cransac M; Moreau JF; Ragnaud JM; Dupon M; Fleury H; Lafon ME
    HIV Med; 2003 Apr; 4(2):120-6. PubMed ID: 12702132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy.
    Arizcorreta A; Márquez M; Fernández-Gutiérrez C; Guzmán EP; Brun F; Rodríguez-Iglesias M; Girón-González JA
    Clin Exp Immunol; 2006 Nov; 146(2):270-7. PubMed ID: 17034579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment.
    Massanella M; Tural C; Papagno L; Garcia E; Jou A; Bofill M; Autran B; Clotet B; Blanco J
    Antivir Ther; 2010; 15(3):333-42. PubMed ID: 20516553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modifications of T-lymphocyte subsets before and during interferon and ribavirin treatment for chronic hepatitis C infection.
    Neau-Cransac M; Foucher J; Ledinghen VD; Bernard PH; Legrand E; Lafon ME
    Viral Immunol; 2005; 18(1):197-204. PubMed ID: 15802964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy?
    Lee S; Hammond T; Watson MW; Flexman JP; Cheng W; Fernandez S; Price P
    Clin Exp Immunol; 2010 Jul; 161(1):118-26. PubMed ID: 20408862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical efficacy of pegylated interferon in patients co-infected with HIV and HCV who failed standard interferon therapy].
    Ke YC; Li LH; Hu FY; He Y; Lan Y; Chen XJ; Tang XP; Cai WP
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):181-5. PubMed ID: 27095760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
    J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
    N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients.
    Neau D; Trimoulet P; Winnock M; Rullier A; Le Bail B; Lacoste D; Ragnaud JM; Bioulac-Sage P; Lafon ME; Chêne G; Dupon M;
    Clin Infect Dis; 2003 Jun; 36(12):1564-71. PubMed ID: 12802757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients.
    Najafi Fard S; Schietroma I; Corano Scheri G; Giustini N; Serafino S; Cavallari EN; Pinacchio C; De Girolamo G; Ceccarelli G; Scagnolari C; Vullo V; d'Ettorre G
    Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):319-329. PubMed ID: 29279268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
    Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
    AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The preliminary efficacy of interferon-alpha and ribavirin combination treatment of chronic hepatitis C in HIV-infected patients.
    Zheng YH; Zhang CY; He Y; Zhou HY; Zou W; Ding PP; Huang L; Li H
    Chin Med J (Engl); 2005 Jul; 118(14):1195-200. PubMed ID: 16117865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C.
    Furusyo N; Kubo N; Toyoda K; Takeoka H; Nabeshima S; Murata M; Nakamuta M; Hayashi J
    Antiviral Res; 2005 Jul; 67(1):46-54. PubMed ID: 15913800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
    Dominguez S; Ghosn J; Valantin MA; Schruniger A; Simon A; Bonnard P; Caumes E; Pialoux G; Benhamou Y; Thibault V; Katlama C
    AIDS; 2006 May; 20(8):1157-61. PubMed ID: 16691067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.
    Laguno M; Murillas J; Blanco JL; Martínez E; Miquel R; Sánchez-Tapias JM; Bargallo X; García-Criado A; de Lazzari E; Larrousse M; León A; Loncá M; Milinkovic A; Gatell JM; Mallolas J
    AIDS; 2004 Sep; 18(13):F27-36. PubMed ID: 15316335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.
    Buti M; Olive G; Stalgis C; Esteban R; Guardi J
    Dig Dis Sci; 2000 Apr; 45(4):685-9. PubMed ID: 10759235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.